Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma

Core Insights - Candel Therapeutics announced preclinical results demonstrating the potent antitumor activity of CAN-3110 in melanoma models, suggesting potential for indication expansion beyond high-grade glioma [1][4] - CAN-3110 is a first-in-class oncolytic viral immunotherapy designed to target Nestin-expressing cancer cells, showing dual activity for oncolysis and immune activation [2][6] - The data presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting indicates significant tumor-specific cytotoxicity and systemic immune activation in melanoma models [4][5] Company Overview - Candel Therapeutics is a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies for cancer treatment [7] - The company has established two clinical-stage platforms based on genetically modified adenovirus and herpes simplex virus (HSV) constructs [7] - CAN-3110 is currently in a phase 1b clinical trial for recurrent high-grade glioma, with previous results indicating improved median overall survival compared to historical controls [6][7] Research Findings - The poster presentation titled "Therapeutic potential of CAN-3110 in Ras-Raf pathway altered melanoma" highlights the mechanism of action and antitumor activity of CAN-3110 in preclinical melanoma models [3] - Preclinical data showed dose-dependent inhibition of tumor growth and tumor regression in melanoma-bearing mice treated with CAN-3110 [4] - The treatment was well-tolerated in animal models, with no dose-limiting toxicity reported [6]